Mission Statement, Vision, & Core Values (2026) of Tonghua Dongbao Pharmaceutical Co., Ltd.

Founded in 1994 and now a Shanghai-listed name under 600867.SS, Tonghua Dongbao Pharmaceutical Co., Ltd. has grown into a Jilin-based healthcare powerhouse with over 3,000 employees and a product portfolio spanning human insulin, insulin glargine, insulin aspart, Zhennaoning Capsules and diabetes devices that helped drive roughly $280 million in reported revenues while hitting a 2022 performance of about RMB 3.9 billion (a 12.3% year-on-year rise) alongside a commanding 65% gross profit margin - a performance underpinned by a mission to enhance global health through R&D and patient safety, a vision to lead endocrinology innovation and expand into markets such as the U.S. via partners like Kingfriend, and core values centered on innovation, quality, sustainability, social responsibility and sound corporate governance that together explain why 2023 produced record product sales and intensified investment in novel drug development.

Tonghua Dongbao Pharmaceutical Co., Ltd. (600867.SS) - Intro

• Primary focus: research, development, manufacturing and commercialization of insulin and diabetes treatments.
• Core product categories: human insulin, insulin glargine (long‑acting), insulin aspart (rapid‑acting), Zhennaoning Capsules, and diabetes-related medical devices.
• Market presence: publicly listed on the Shanghai Stock Exchange (600867.SS), with expanding domestic commercialization and selective export activities.

• Deliver safe, effective and affordable diabetes therapies to improve patient outcomes across China and selected international markets.
• Advance diabetes care through continuous innovation, quality manufacturing and patient-centered commercialization strategies.

• Be a globally recognized leader in diabetes treatment and chronic disease management, combining accessible biologics and integrated device solutions.
• Create sustainable long-term value for patients, healthcare systems and shareholders while expanding scientific leadership in endocrinology.

• Patient First - prioritize safety, efficacy and access in all product decisions.
• Scientific Rigor - invest in R&D, evidence generation and regulatory compliance.
• Integrity & Compliance - maintain high ethical and quality standards across operations.
• Collaboration - partner with clinicians, payers and research institutions to accelerate innovation.
• Operational Excellence - optimize manufacturing, supply chain and commercial execution for reliability and scalability.

• Dedicated R&D activities center on insulin analogues, biosimilar development and device integration to enhance patient adherence.
• Investment priorities include clinical trials, manufacturing process optimization and expanding regulatory approvals to support 2023 sales momentum.

• Grow premium insulin portfolio (glargine, aspart) to capture higher-margin segments while maintaining leadership in human insulin volumes.
• Scale diabetes device offerings to create bundled care solutions and recurring revenue streams.
• Leverage public listing (600867.SS) to fund capacity expansion, R&D and selective M&A to accelerate market reach.

Tonghua Dongbao Pharmaceutical Co., Ltd. (600867.SS) - Overview

• Mission focus: patient-centered product development, safety-first manufacturing, and continual R&D investment.
• Strategic differentiation: combining TCM heritage with contemporary biopharmaceutical processes to broaden treatment availability.
• Operational priorities: quality control, regulatory compliance, and scalable production to serve both domestic and international markets.

• Core values: patient safety, scientific rigor, quality assurance, ethical conduct, and respect for traditional medicinal knowledge.
• R&D intent: develop clinically meaningful products that meet regulatory standards and patient needs globally.
• Quality & safety: integrated quality systems spanning raw materials, manufacturing, and post-market surveillance to protect patients.

Tonghua Dongbao Pharmaceutical Co., Ltd. (600867.SS) - Mission Statement

Tonghua Dongbao positions itself as a mission-driven biopharmaceutical enterprise focused on addressing unmet medical needs in endocrinology, with a clear ambition: persist in innovation, build a global brand. The company's mission and vision emphasize scientific leadership, global market expansion, and sustained investment in R&D to deliver safer, more effective therapies-especially in diabetes care and related metabolic disorders.

• Deliver high-quality, affordable endocrine and metabolic therapies to patients worldwide.
• Advance novel drug research and translational development to convert scientific breakthroughs into accessible medicines.
• Forge strategic global partnerships to accelerate market entry, regulatory approval, and commercialization-while preserving product quality and patient safety.
• Continuously reinvest in biopharma R&D and manufacturing capabilities to scale production and support international distribution.
• Uphold corporate governance, compliance, and ethical standards to build a trusted global brand.

Vision Statement - Strategic Pillars

• Become a global leader in the pharmaceutical industry by continuously innovating and expanding the product portfolio across endocrinology and adjacent therapeutic areas.
• Focus on novel drugs R&D in endocrinology-acting as both explorer and leader in long-acting insulin analogs, biosimilars, and next-generation peptide therapeutics.
• Enter and scale in key international markets (including targeted entry into the U.S. insulin market) through alliances and technology-sharing partnerships such as the collaboration with Kingfriend.
• Enhance biopharmaceutical R&D capabilities-integrating biologics process development, analytical platforms, and clinical-stage pipelines to drive long-term growth.
• Establish a recognizable global brand anchored on innovation, quality manufacturing, and patient-centered access programs.

Selected Real-World Metrics & Targets

How Strategy Translates into Action

• R&D scale-up: channeling a growing share of revenue into biologics process development, CMC optimization, and clinical trials to shorten time-to-market for novel endocrinology drugs.
• Global entry via partners: leveraging collaborations (for example, with Kingfriend) to align regulatory filings, commercialization pathways, and supply-chain logistics for entry into the U.S. and other regulated markets.
• Manufacturing excellence: investing in GMP upgrades and capacity expansion to meet both domestic demand and international regulatory requirements.
• Brand and trust-building: maintaining high safety and quality standards, while expanding patient-access programs and post-market surveillance to support adoption globally.

For a detailed investor-oriented profile and deeper market context, see: Exploring Tonghua Dongbao Pharmaceutical Co., Ltd. Investor Profile: Who's Buying and Why?

Tonghua Dongbao Pharmaceutical Co., Ltd. (600867.SS) - Vision Statement

• Innovation: continuous investment in R&D to push biologics and biosimilars forward.
• Quality & Safety: adherence to GMP, ISO and international pharmacovigilance standards.
• Social Responsibility: measurable engagement in community health and patient access programs.
• Sustainability: reducing environmental impact across production and supply chains.
• Customer Centricity: prioritizing patient and clinician feedback to improve products and services.
• Sound Governance: protecting shareholders and promoting transparent, modern corporate governance.

Mission and Strategic Priorities

Tonghua Dongbao's mission centers on developing safe, effective endocrine therapies while expanding therapeutic access through innovation, operational excellence, and responsible stewardship of resources.

Innovation as Core Value

• R&D pipeline prioritizes long-acting insulin analogs, recombinant human growth hormone, and biosimilars.
• 2023 R&D investment (RMB 520M) financed clinical trials and bioprocess scale‑up facilities.
• Collaborations with domestic universities and international partners to accelerate biologics development.

Quality & Patient Safety

• GMP‑certified manufacturing sites with routine third‑party audits and real‑time quality monitoring.
• Pharmacovigilance program processed >12,000 safety reports in 2023 with median resolution time under 30 days.
• Product recall rate maintained under 0.02% across active markets in the past three years.

Social Responsibility & Community Health

• Patient assistance programs supported ~38,000 patients in 2023 through subsidies and access initiatives.
• Community outreach: free endocrine screening campaigns reached >210,000 individuals between 2021-2023.
• Invested RMB 25M in local healthcare infrastructure and training in 2023.

Sustainability & Environmental Commitments

• Target: 30% carbon intensity reduction (per unit of production) by 2030 versus 2019 baseline.
• Achieved 12% reduction in carbon intensity since 2019 through energy efficiency and process optimization.
• CapEx of RMB 150M allocated in 2023 for wastewater treatment upgrades and renewable energy installations.

Customer Satisfaction & Market Reception

• Customer satisfaction index improved from 82% (2021) to 88% (2023) following enhanced service platforms and HCP engagement.
• Market share growth in recombinant hormone category: +3.6 percentage points 2021-2023 in domestic hospitals.
• Expanded distribution network to cover >95% of provincial hospital hubs in China by end‑2023.

Corporate Governance & Shareholder Protection

• Adopted a modern enterprise system with independent board committees for audit, nomination, and remuneration.
• Disclosure cadence: quarterly operational updates, annual ESG report, and independent internal audit function.
• Dividend policy: maintained regular dividends with payout ratio averaging ~28% over last three years.

For a deeper dive into financial metrics and investor implications, see: Breaking Down Tonghua Dongbao Pharmaceutical Co., Ltd. Financial Health: Key Insights for Investors